WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising an isolated population of extracellular vesicles (EVs) derived from non-transformed neural progenitor (NP) cells, and a pharmaceutically acceptable carrier.

2. The pharmaceutical composition of claim 1, wherein the NP cells are human cells.

3. The pharmaceutical composition of claim 1, wherein the NP cells are derived from human pluripotent stem cells.

4. The pharmaceutical composition of claim 1, wherein the NP cells are derived from human induced pluripotent stem cells.

5. The pharmaceutical composition of claim 1, wherein the NP cells are derived from human embryonic stem cells.

6. The pharmaceutical composition of claim 1, wherein the NP cells are SOX 1+, SOX 2+ and OCT4-.

7. The pharmaceutical composition of any one of claims 1-6, wherein the EVs comprise one or more protein biomarkers set forth in Table 9.

8. A composition comprising extracellular vesicles (EVs) obtained by culturing non-transformed neural progenitor (NP) cells derived from human pluripotent stem cells in cell culture medium under conditions and for a time sufficient to produce EVs, and isolating said EVs from the culture medium.

9. The composition of claim 8, wherein the human pluripotent stem cells are embryonic stem cells.

10. The composition of claim 8, wherein the human pluripotent stem cells are induced pluripotent stem cells.

11. The composition of claim 8, wherein the neural progenitor cells are SOX 1+, SOX 2+ and OCT4-.

12. The composition of any one of claims 8 to 11, wherein the EVs comprise one or more protein biomarkers set forth in Table 9.

13. The composition of any one of claims 1 to 12, further comprising one or more neurotrophic factors.

14. The composition of claim 13, wherein the one or more neurotrophic factors are selected from the group consisting of leukemia inhibitory factor (LIF), brainderived neurotrophic factor (BDNF), ciliary neurotrophic factor (CTNF), epidermal growth factor receptor (EGF), basic fibroblast growth factor (bFGF), FGF-6, glialderived neurotrophic factor (GDNF), ciliary neurotrophic factor (CTNF), granulocyte colony-stimulating factor (GCSF), hepatocyte growth factor (HGF), IFN-γ, insulin-like growth factor binding protein (IGFBP-2), IGFBP-6, IL-1ra, IL-6, IL-8, monocyte chemotactic protein (MCP-1), mononuclear phagocyte colony-stimulating factor (MCSF), neurotrophic factors (NT3), tissue inhibitor of metalloproteinases (TIMP-1), TIMP-2, tumor necrosis factor (TNF-β), vascular endothelial growth factor (VEGF), VEGF-D, urokinase plasminogen activator receptor (uPAR), bone morphogenetic protein 4 (BMP4), IL1-a, IL-3, leptin, stem cell factor (SCF), stromal cell-derived factor-1 (SDF-1), platelet derived growth factor-BB (PDGFBB), transforming growth factors beta (TGFβ-1) and TGFβ-3.

15. The composition of any one of claims 1 to 14, wherein the EVs are suspended in a hydrogel scaffold.

16. The composition of any one of claims 1 to 15, further comprising a protease inhibitor, a RNAse inhibitor, or combination thereof.

17. The composition of any one of claims 1 to 16, wherein the composition comprises about 1 mg to about 750 mg of EVs.

18. The composition of any one of claims 1 to 17, wherein the EVs further comprise a small molecule.

19. The composition of any one of claims 1 to 17, wherein the EVs further comprise an antisense oligonucleotide or a siRNA.

20. The composition of any one of claims 1 to 17, wherein the EVs further comprise an exogenous peptide or an exogenous protein.

21. The composition of any one of claims 1 to 17, wherein the EVs further comprise an antibody.

22. The composition of any one of claims 1 to 21, wherein the EVs comprise exosomes.

23. The composition of any one of claims 1 to 22, wherein the EVs are about 20 nm to 10 μm in size.

24. The composition of any one of claims 1 to 23, wherein the EVs are about 20 nm to about 150 nm in size.

25. Use of a pharmaceutical composition comprising extracellular vesicles (EVs) derived from non-transformed neural progenitor (NP) cells in the manufacture of a medicament for treating a subject who has suffered a stroke.

26. Use of a pharmaceutical composition comprising extracellular vesicles (EVs) derived from non-transformed neural progenitor (NP) cells in the manufacture of a medicament for treating a subject who has suffered a spinal cord injury, a traumatic brain injury, or a neurodegenerative disease.

27. The use of claim 26, wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, a Parkinson's-related disorder, Huntington's disease, amyotrophic lateral sclerosis, prion disease, motor neuron disease (MND), spinocerebellar ataxia (SCA) or spinal muscular atrophy (SMA).

28. The use of any one of claims 25 to 27, wherein the NP cells are human cells.

29. The use of claim 28, wherein the NP cells are derived from human pluripotent stem cells.

30. The use of claim 28, wherein the NP cells are derived from human induced pluripotent stem cells.

31. The use of claim 28, wherein the NP cells are derived from human embryonic stem cells.

32. The use of any one of claims 25 to 31, wherein the NP cells express one or more markers selected from the group consisting of nestin, SOX1, and SOX2, and do not express OCT4.

33. The use of any one of claims 25 to 32, wherein the medicament comprises about 1 mg to about 750 mg of EVs.

34. The use of any one of claims 25 to 33, wherein the EVs comprise exosomes.

35. The use of any one of claims 25 to 34, wherein the EVs are about 20 nm to 10 μm in size.

36. The use of any one of claims 25 to 35, wherein the EVs are about 20 nm to about 150 nm in size.

37. The use of any one of claims 25 to 36, wherein the EVs further comprise an agent selected from the group consisting of a small molecule, an antisense oligonucleotide, a siRNA, an exogenous peptide, an exogenous protein, or an antibody.

38. The use of any one of claims 25 and 28 to 37, wherein the subject has suffered an ischemic stroke.

39. The use of any one of claims 25 and 28 to 37, wherein the subject has suffered a hemorrhagic stroke.

40. The use of any one of claims 25 to 39, wherein the medicament is formatted for intravenous administration.

41. The use of any one of claims 25 to 39, wherein the medicament is formatted for administration via a route of delivery selected from intrathecal, intraperitoneal (IP), oral, intranasal, or direct delivery into the brain.

42. The use of any one of claims 25 and 28 to 41, wherein the medicament is to be initially administered to the subject within 24 hours following a stroke.

43. The use of any one of claims 25 and 28 to 41, wherein the medicament is to be administered to the subject 1-4 weeks following a stroke.

44. The use of any one of claims 25 to 43, wherein the medicament reduces swelling in the brain of the subject and/or reduces inflammation in the subject.

45. The use of any one of claims 25 to 44, wherein the medicament improves sensorimotor function in the subject and/or improves behavioral function in the subject.

46. The use of any one of claims 25 to 45, wherein the medicament improves the likelihood of survival of the subject.

47. The use of any one of claims 25 to 46, wherein the medicament reduces lesion volume in the subject.

48. The use of any one of claims 25 and 28 to 47, wherein the medicament is to be administered to the subject in conjunction with an additional bioactive agent useful in the treatment of stroke.

49. The use of claim 48, wherein the additional bioactive agent is selected from the group consisting of a salicylate, a thrombolytic agent, and a platelet aggregation inhibitor.

50. The use of claim 49, wherein the additional bioactive agent is selected from the group consisting of aspirin, alteplase, and clopidogrel.